Core Viewpoint - The company held its 2024 annual performance briefing, where it engaged with investors and addressed various inquiries regarding its business strategies and performance metrics. Group 1: Company Performance - In 2024, the company achieved total revenue of 1.349 billion yuan, representing a year-on-year growth of 16.93% [6] - The net profit attributable to shareholders was 113 million yuan, an increase of 11.54% year-on-year [6] - The company's proprietary drug business generated 283 million yuan in revenue, marking a 44.31% increase compared to the previous year [6][7] Group 2: Business Strategy - The company is focused on a management-style medical strategy, which has led to a revenue growth of 25%-30% in its pharmaceutical and medical services sectors [4] - The company aims to enhance its digital health management services, covering the entire patient lifecycle, to improve drug sales and patient compliance [4][7] - The company plans to optimize its liver disease patient management system in response to the "Healthy China 2030" initiative [4] Group 3: Market Position and Future Outlook - The domestic market accounted for 36.72% of revenue, while the international market contributed 63.28% in 2024 [4] - The company is committed to becoming a professional and international management-style medical group, focusing on liver cancer screening and management [4][7] - The company anticipates that the market for its products will enter a rapid growth phase following the approval of the MASH indication by the FDA [4][8] Group 4: Product and Service Development - The company has developed a full-cycle management solution for liver disease, integrating screening, diagnosis, and treatment [4][7] - The FibroScan Go and box products have been installed in 651 units globally, becoming new revenue growth points for the company [7] - The company is enhancing its marketing strategies for its proprietary drugs and expanding its e-commerce channels to sustain high growth rates [6][7]

证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2025-003 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | | --- | --- | --- | | | □媒体采访 √业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 □其他 （请文字说明其他活动内容） | | | 参与单位名称及人员姓名 | 参与公司 2024 年度业绩说明会的投资者 | | | 时间 | 2025 年 5 月 9 日 (周五) 下午 15:00~17:00 | | | 地点 | 全景网"投资者关系互动平台"（http://ir.p5w.net） | | | | 董事长、总经理：王冠一 | | | 上市公司接待人员姓名 | 副总经理、财务总监：沈治国 | | | | 董事会秘书：孙秀珍 | | | | 独立董事：郭晋龙 | | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | | 1、请问泰拉克里昂公司预计何时提交 FDA.目前国内市场进 | | | | 展如何？采用什么样的商业模式？什么时候能为福瑞贡献营收。 ...